Back to top

CLDX Maintains Overweight Rating -- Price Target Raised to $72

CLDX Maintains Overweight Rating -- Price Target Raised to $72

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Celldex Therapeutics, Inc. (CLDX)